Explore IQVIA by region
As a global community, IQVIA continuously invests and commits to advancing human health.
Europe
Asia & Oceania
Middle East & Africa
EMEA Thought Leadership
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn More
Commercial Solutions
Commercial Solutions (desc)
Contract Sales and Medical Solutions
Contract Sales and Medical Solutions (desc)
Financial Services
Financial Services (desc)
Information Solutions
Information Solutions (desc)
Medical Affairs
Medical Affairs (desc)
Real World Evidence
Real World Evidence (desc)
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn More
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn More
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn More
The IQVIA difference
Explore IQVIA by region
As a global community, IQVIA continuously invests and commits to advancing human health.
Americas
Europe
Asia & Oceania
Middle East & Africa
EMEA Thought Leadership
WHITE PAPER
Challenges Facing CRISPR Gene Therapy Commercialization
Jul 27, 2023
- Locations
- United States
- Challenges Facing CRISPR Gene Therapy Commercialization
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene therapy has recently emerged as a promising technology for treating genetic disorders previously considered incurable. Since its conception in 2012, application and optimization of CRISPR technology has rapidly expanded. While this innovative technology holds almost limitless therapeutic targeting potential, it is not without its challenges.